A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates
暂无分享,去创建一个
[1] T. Fletcher,et al. Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections , 2020, medRxiv.
[2] F. Blyth,et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. , 2012, Journal of clinical epidemiology.
[3] Are SARS-CoV-2 seroprevalence estimates biased? , 2020, The Journal of infectious diseases.
[4] C. Reusken,et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak , 2020 .
[5] H. Rothan,et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.
[6] Daniel Eichner,et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. , 2020, JAMA.
[7] Linus Wilson. SARS-CoV-2, COVID-19, Infection Fatality Rate (IFR) Implied by the Serology, Antibody, Testing in New York City , 2020, SSRN Electronic Journal.
[8] Kai Liu,et al. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients , 2020, Journal of Infection.
[9] U. Seljak,et al. Total COVID-19 Mortality in Italy: Excess Mortality and Age Dependence through Time-Series Analysis , 2020, medRxiv.
[10] S. Eubank,et al. Commentary on Ferguson, et al., “Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand” , 2020, Bulletin of Mathematical Biology.
[11] Kun Chen,et al. Characteristics of COVID-19 infection in Beijing , 2020, Journal of Infection.
[12] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[13] P. Simon. Robust Estimation of Infection Fatality Rates during the Early Phase of a Pandemic , 2020, medRxiv.
[14] David Dongkyung Kim,et al. Estimating case fatality rates of COVID-19 , 2020, The Lancet Infectious Diseases.
[15] Lin Yang,et al. Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong. , 2013, American journal of epidemiology.
[16] R. Eggo,et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[17] B. Bassett. Strict Lower Bound on the COVID-19 Fatality Rate in Overwhelmed Healthcare Systems , 2020, medRxiv.
[18] M. Wener,et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho , 2020, medRxiv.
[19] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[20] Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications , 2020, European Journal of Epidemiology.
[21] C. Bridges,et al. Estimating influenza-associated deaths in the United States. , 2009, American journal of public health.
[22] An Empirical Estimate of the Infection Fatality Rate of COVID-19 from the First Italian Outbreak , 2020 .
[23] S. Soubeyrand,et al. Mechanistic-statistical SIR modelling for early estimation of the actual number of cases and mortality rate from COVID-19 , 2020 .
[24] Dena Goffman,et al. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery , 2020, The New England journal of medicine.
[25] R. Krüger,et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. , 2020, medRxiv.
[26] S. Hegde,et al. The important role of serology for COVID-19 control , 2020, The Lancet Infectious Diseases.
[27] H. Ullum,et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.
[28] Kari Stefansson,et al. Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.
[29] P. Giorgi Rossi,et al. Case fatality rate in patients with COVID-19 infection and its relationship with length of follow up☆ , 2020, Journal of Clinical Virology.
[30] J. Ioannidis,et al. COVID-19 antibody seroprevalence in Santa Clara County, California , 2020, medRxiv.
[31] A. Basu. Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United States. , 2020, Health affairs.
[32] S. Bosari,et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak , 2020, medRxiv.
[33] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.
[34] F. Turkheimer,et al. COVID-19: Recovering estimates of the infected fatality rate during an ongoing pandemic through partial data , 2020, medRxiv.
[35] M. Paradisi,et al. An empirical estimate of the infection fatality rate of COVID-19 from the first Italian outbreak , 2020, medRxiv.
[36] Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital , 2020, Nature Communications.
[37] P. Klenerman,et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure , 2020, medRxiv.
[38] Richard E. Grewelle,et al. Estimating the Global Infection Fatality Rate of COVID-19 , 2020, medRxiv.
[39] C. Kahathuduwa,et al. Case fatality rate in COVID-19: a systematic review and meta-analysis , 2020, medRxiv.
[40] M. Nöthen,et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event , 2020 .
[41] A. Heidarzadeh,et al. Seroprevalence of COVID-19 virus infection in Guilan province, Iran , 2020, medRxiv.
[42] Cesar G Victora,et al. Remarkable variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey in 27 states , 2020, medRxiv.
[43] M. Wener,et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho , 2020, Journal of Clinical Microbiology.
[44] Yan Bai,et al. Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.
[45] Elisabeth Mahase,et al. Covid-19: UK starts social distancing after new model points to 260 000 potential deaths , 2020, BMJ.
[46] COVID-19 Serological Tests: How Well Do They Actually Perform? , 2020, Diagnostics.
[47] M. Gomes,et al. Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics , 2020, medRxiv.
[48] B. Horta,et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil , 2020, Nature Medicine.
[49] A. Ahlbom,et al. Excess mortality from COVID-19: weekly excess death rates by age and sex for Sweden and its most affected region , 2020, medRxiv.
[50] M. Lipsitch. Estimating case fatality rates of COVID-19 , 2020, The Lancet Infectious Diseases.
[51] Dusan Petrovic,et al. Appendix: Seroprevalence of anti-SARS-COV-2 IgG antibodies in a population-based sample from Geneva, Switzerland , 2020 .
[52] Sheng Zhang,et al. False negative of RT‐PCR and prolonged nucleic acid conversion in COVID‐19: Rather than recurrence , 2020, Journal of medical virology.
[53] J. Lessler,et al. Estimating the burden of SARS-CoV-2 in France , 2020, Science.
[54] Hiroshi Nishiura,et al. The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights , 2020, Journal of clinical medicine.
[55] J. Van Wyk,et al. Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys , 2020, medRxiv.
[56] S. Lauer,et al. Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland , 2020, medRxiv.
[57] A. Gylfason,et al. Early Spread of SARS-Cov-2 in the Icelandic Population , 2020, medRxiv.
[58] K. Iwata,et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study , 2020, Clinical Epidemiology and Global Health.
[59] A. Torres,et al. The value of serology testing to manage SARS-CoV-2 infections , 2020, European Respiratory Journal.
[60] J. Ioannidis,et al. The infection fatality rate of COVID-19 inferred from seroprevalence data , 2020, medRxiv.
[61] Andrea Benedetti,et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis , 2020, BMJ.
[62] N. Linton,et al. Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases , 2020, Journal of clinical medicine.
[63] A. Markotić,et al. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia , 2020, medRxiv.
[64] C. Whittaker,et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand , 2020 .